网站大量收购独家精品文档,联系QQ:2885784924

ketosis_and_diabetic_ketoacidosis_in_response_to_sglt2_inhibitors_basic_mechanisms_and_therapeutic_perspectives.d.酮症和糖尿病酮症酸中毒sglt2抑制剂的基本机制和治疗前景。_Image_Marked.pdf

ketosis_and_diabetic_ketoacidosis_in_response_to_sglt2_inhibitors_basic_mechanisms_and_therapeutic_perspectives.d.酮症和糖尿病酮症酸中毒sglt2抑制剂的基本机制和治疗前景。_Image_Marked.pdf

  1. 1、本文档共28页,可阅读全部内容。
  2. 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
  3. 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  4. 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
ketosis_and_diabetic_ketoacidosis_in_response_to_sglt2_inhibitors_basic_mechanisms_and_therapeutic_perspectives.d.酮症和糖尿病酮症酸中毒sglt2抑制剂的基本机制和治疗前景。_Image_Marked

Ketosis and Diabetic Ketoacidosis in Response to SGLT2 Inhibitors: Basic Mechanisms and Therapeutic Perspectives Hongyu Qiu, MD1,2, Aleksandra Novikov, MD2,3, and Volker Vallon, MD2,3* 1 Department of Nephrology, West China Hospital, Sichuan University, Chengdu Sichuan, P. R. China 2 Division of Nephrology Hypertension, Departments of Medicine and Pharmacology, University of California San Diego, La Jolla, California 92093 3 VA San Diego Healthcare System, San Diego, California 92161 Running head: SGLT2 inhibition and ketoacidosis Corresponding author: Volker Vallon, MD UC San Diego and VA San Diego Healthcare System 3350 La Jolla Village Dr. (9151) San Diego, CA 92161 Phone: (001) 858-552-8585 ext 5945 Fax: (001) 858- 642-1438 E-mail: vvallon@ This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/dmrr.2886 This article is protected by copyright. All rights reserved. Abstract Inhibitors of the sodium-glucose cotransporter SGLT2 are a new class of anti-hyperglycemic drugs that have been approved for the treatment of type 2 diabetes mellitus (T2DM). These drugs inhibit glucose reabsorption in the proximal tubules of the kidney thereby enhancing glucosuria and lowering blood glucose levels. Additional consequences and benefits include a reduction in body weight, uric acid levels, and blood pressure. Moreover, SGLT2 inhibition can have protective effects on the kidney and cardiovascular system in patients with T2DM and high cardiovascular risk. However, a potential side effect that has been reported with SGLT2 inhibitors in patients with T2DM and particularly during off-label use in patients with type 1 diabetes is diabetic ketoacidosis

您可能关注的文档

文档评论(0)

seunk + 关注
实名认证
内容提供者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档